The results were further verified in xenograft mouse models, in which the ability of cetuximab to reduce tumor growth rate and volume was hindered by the overexpression of IGF2BP3 and promoted by the downregulation of IGF2BP3 (Fig. 5e, f). Here, IGF2BP3 is linked to neoplasm.